Capivasertib, a selective oral AKT inhibitor, has demonstrated substantial efficacy in hormone receptor–positive, HER2–negative advanced breast cancer, particularly among patients with AKT pathway mutations. The gene discussed is AKT1; the disease is breast carcinoma.